Merck & Co. Inc. has signed at least 12 diabetes-related deals since the pharma and Bristol-Myers Squibb Co. terminated a co-development deal for BMS's Pargluva muraglitazar in December 2005. At least six of the 12 deals are ongoing. (A) Ezose Sciences Inc. declined to confirm deal is ongoing, and Merck was unable to provide a response in time for publication; Sources: BCIQ: BioCentury Online Intelligence; Merck; SEC filings

Partner

Type

Deal

Financials

Date

Abide Therapeutics Inc.

Discovery

Discover, develop and commercialize small molecules against three serine hydrolase targets to treat metabolic diseases, including Type II diabetes

Up to $430M from upfront payment, research funding and milestones; royalties

May-13